Brian Shiner1, Jenna A Forehand2, Luke Rozema2, Martin Kulldorff3, Bradley V Watts4, Marina Trefethen2, Tammy Jiang5, Krista F Huybrechts6, Paula P Schnurr7, Matthew Vincenti4, Jiang Gui8, Jaimie L Gradus5. 1. White River Junction Veterans Affairs Medical Center, White River Junction, Vermont; Veterans Administration National Center for PTSD, White River Junction, Vermont; Geisel School of Medicine at Dartmouth, Hanover, New Hampshire. Electronic address: brian.shiner@va.gov. 2. White River Junction Veterans Affairs Medical Center, White River Junction, Vermont. 3. Harvard Medical School, Boston, Massachusetts; Brigham and Women's Hospital, Boston, Massachusetts. 4. White River Junction Veterans Affairs Medical Center, White River Junction, Vermont; Geisel School of Medicine at Dartmouth, Hanover, New Hampshire. 5. Boston University School of Public Health, Boston, Massachusetts. 6. Harvard Medical School, Boston, Massachusetts; Brigham and Women's Hospital, Boston, Massachusetts; Boston University School of Public Health, Boston, Massachusetts; Harvard T.H. Chan School of Public Health, Boston, Massachusetts. 7. Veterans Administration National Center for PTSD, White River Junction, Vermont; Geisel School of Medicine at Dartmouth, Hanover, New Hampshire. 8. Geisel School of Medicine at Dartmouth, Hanover, New Hampshire.
Abstract
BACKGROUND: Despite the prevalence and negative impact of posttraumatic stress disorder (PTSD), there are few medications approved by the U.S. Food and Drug Administration for treatment, and approved medications do not work well enough. We leveraged large-scale electronic health record data to identify existing medications that may be repurposed as PTSD treatments. METHODS: We constructed a mechanistic tree of all Food and Drug Administration-approved medications and used the tree-based scan statistic to identify medications associated with greater than expected levels of clinically meaningful improvement in PTSD symptoms using electronic health record data from the U.S. Department of Veterans Affairs. Our cohort included patients with a diagnosis of PTSD who had repeated symptom measurements using the PTSD Checklist over a 20-year period (N = 168,941). We calculated observed numbers based on patients taking each drug or mechanistically related class of drugs and the expected numbers based on the tree as a whole. RESULTS: Medications typically used to treat PTSD, such as the Food and Drug Administration-approved agent sertraline, were associated with improvement in PTSD symptoms, but the effects were small. Several, but not all, direct-acting antivirals used in the treatment of hepatitis C virus demonstrated a strong association with PTSD improvement. The finding was robust to a sensitivity analysis excluding patients who received established PTSD treatments, including trauma-focused psychotherapy, concurrent with hepatitis treatment. CONCLUSIONS: Our exploratory approach both demonstrated findings that are consistent with what is known about pharmacotherapy for PTSD and uncovered a novel class of medications that may improve PTSD symptoms. Published by Elsevier Inc.
BACKGROUND: Despite the prevalence and negative impact of posttraumatic stress disorder (PTSD), there are few medications approved by the U.S. Food and Drug Administration for treatment, and approved medications do not work well enough. We leveraged large-scale electronic health record data to identify existing medications that may be repurposed as PTSD treatments. METHODS: We constructed a mechanistic tree of all Food and Drug Administration-approved medications and used the tree-based scan statistic to identify medications associated with greater than expected levels of clinically meaningful improvement in PTSD symptoms using electronic health record data from the U.S. Department of Veterans Affairs. Our cohort included patients with a diagnosis of PTSD who had repeated symptom measurements using the PTSD Checklist over a 20-year period (N = 168,941). We calculated observed numbers based on patients taking each drug or mechanistically related class of drugs and the expected numbers based on the tree as a whole. RESULTS: Medications typically used to treat PTSD, such as the Food and Drug Administration-approved agent sertraline, were associated with improvement in PTSD symptoms, but the effects were small. Several, but not all, direct-acting antivirals used in the treatment of hepatitis C virus demonstrated a strong association with PTSD improvement. The finding was robust to a sensitivity analysis excluding patients who received established PTSD treatments, including trauma-focused psychotherapy, concurrent with hepatitis treatment. CONCLUSIONS: Our exploratory approach both demonstrated findings that are consistent with what is known about pharmacotherapy for PTSD and uncovered a novel class of medications that may improve PTSD symptoms. Published by Elsevier Inc.
Authors: Charles W Hoge; Artin Terhakopian; Carl A Castro; Stephen C Messer; Charles C Engel Journal: Am J Psychiatry Date: 2007-01 Impact factor: 18.112
Authors: John H Krystal; Lori L Davis; Thomas C Neylan; Murray A Raskind; Paula P Schnurr; Murray B Stein; Jennifer Vessicchio; Brian Shiner; Theresa C Gleason; Grant D Huang Journal: Biol Psychiatry Date: 2017-03-14 Impact factor: 13.382
Authors: Brian Shiner; Christine Leonard; Jiang Gui; Sarah Cornelius; Jaimie L Gradus; Paula P Schnurr; Bradley V Watts Journal: Adm Policy Ment Health Date: 2021-01
Authors: Myrela O Machado; Giovanni Oriolo; Beatrice Bortolato; Cristiano A Köhler; Michael Maes; Marco Solmi; Iria Grande; Rocío Martín-Santos; Eduard Vieta; André F Carvalho Journal: J Affect Disord Date: 2016-11-27 Impact factor: 4.839
Authors: Bradley V Watts; Paula P Schnurr; Lorna Mayo; Yinong Young-Xu; William B Weeks; Matthew J Friedman Journal: J Clin Psychiatry Date: 2013-06 Impact factor: 4.384
Authors: Samantha J Moshier; Daniel J Lee; Michelle J Bovin; Gabrielle Gauthier; Alexandra Zax; Raymond C Rosen; Terence M Keane; Brian P Marx Journal: J Trauma Stress Date: 2019-10
Authors: A Patrícia Bento; Anna Gaulton; Anne Hersey; Louisa J Bellis; Jon Chambers; Mark Davies; Felix A Krüger; Yvonne Light; Lora Mak; Shaun McGlinchey; Michal Nowotka; George Papadatos; Rita Santos; John P Overington Journal: Nucleic Acids Res Date: 2013-11-07 Impact factor: 16.971